While the latest macro data confirm the positive orientation of European economic growth, risks in the eurozone remain plentiful.
Targetting companies with 'pricing power'
Daniel Koller, BB Biotech's head of investment, discusses sector growth, innovation and the attractive valuations of fast-growing companies.
Ceremony on 30 June